KOD
Kodiak Sciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$91.35
+6.53%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$86.50
From 52W high−8.53%
Volume1.05M
Market cap$5.74B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$86.50
From 52W high
−8.53%
Volume
1.05M
Market cap
$5.74B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−26.7x
P/E (TTM)
—
RSI (14)
64.0
MomentumView details →
1D Return
+6.53%
YTD Return
+223.94%
SummaryUpdated Jun 1, 2026
Kodiak Sciences Inc. (NASDAQ:KOD) is a clinical-stage biopharmaceutical company founded in 2009 and based in Palo Alto, California. Originally incorporated as Oligasis, LLC, the company changed its name to Kodiak Sciences in September 2015 and went public in October 2018. Kodiak focuses on developing novel therapeutics to treat retinal diseases, with its lead drug candidate currently in late-stage clinical trials for several sight-threatening conditions affecting millions of patients worldwide.
Similar companies
Latest newsMore news →
Kodiak Sciences Inc. announced that it will present clinical data from all three late-stage programs at AAO 2026, including Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted, Phase 3 GLOW2 data for Zenkuda, and Phase 1b APEX data for KSI-101.13d agoRegeneron Pharmaceuticals stock traded lower on Monday, likely in reaction to positive Phase 3 DAYBREAK trial data from Kodiak Sciences for wet age-related macular degeneration.21d agoKodiak Sciences announced that its eye disease drug met its clinical trial goals, sending the company's shares up 123%.22d ago